PLUR
Pluri Inc.
NASDAQ · Healthcare · Biotechnology · IL
$1.34
−2.03%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.1M | 1.3M | 326.0K | 287.0K | 234.0K |
| Cost of Revenue | 874.0K | 682.0K | 4.0K | 9.0K | 1.1M |
| Gross Profit | 205.0K | 654.0K | 322.0K | 278.0K | (819.0K) |
| Operating Expenses | |||||
| R&D Expense | 15.8M | 12.9M | 12.4M | 15.7M | 24.4M |
| SG&A Expense | 10.5M | 10.0M | 10.0M | 11.8M | 17.4M |
| General & Admin Expense | 10.5M | 10.0M | 10.0M | 11.8M | 17.4M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | (1.1M) |
| Total Operating Expenses | 26.2M | 22.8M | 22.5M | 27.5M | 40.8M |
| Cost and Expenses | 27.1M | 23.5M | 22.5M | 27.5M | 41.8M |
| Operating Income (EBIT) | (26.0M) | (22.2M) | (22.2M) | (27.2M) | (41.6M) |
| Non-Operating | |||||
| Interest Income | 727.0K | 1.1M | 1.3M | 1.1M | 581.0K |
| Interest Expense | 930.0K | 873.0K | 866.0K | 843.0K | 887.0K |
| Net Interest Income | (203.0K) | 271.0K | 448.0K | 241.0K | (306.0K) |
| Other Non-Op Income/Expense | (939.0K) | (1.1M) | 814.0K | (1.6M) | 219.0K |
| Non-Operating Income (excl Interest) | 483.0K | 206.0K | (1.7M) | 798.0K | (1.1M) |
| EBT (Pre-Tax Income) | (27.0M) | (23.3M) | (21.3M) | (28.9M) | (41.4M) |
| Income Tax Expense | (21.0K) | (5.0K) | — | — | — |
| Bottom Line | |||||
| Net Income | (26.2M) | (22.6M) | (20.9M) | (28.3M) | (41.2M) |
| Earnings from Cont. Ops | (26.9M) | (23.3M) | (21.3M) | (28.9M) | (41.4M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (26.2M) | (22.6M) | (20.9M) | (28.3M) | (41.2M) |
| Per Share | |||||
| Basic EPS | ($2.87) | ($3.56) | ($3.99) | ($6.18) | ($10.24) |
| Diluted EPS | ($2.87) | ($3.56) | ($3.99) | ($6.18) | ($10.24) |
| Revenue Per Share | $0.11 | $0.21 | $0.06 | $0.06 | $0.06 |
| Shares | |||||
| Basic Shares Outstanding | 10.1M | 6.3M | 5.2M | 4.6M | 4.0M |
| Diluted Shares Outstanding | 10.1M | 6.3M | 5.2M | 4.6M | 4.0M |
| Profitability Metrics | |||||
| EBITDA | (26.0M) | (22.1M) | (20.2M) | (27.7M) | (39.4M) |
| D&A | 498.0K | 316.0K | 253.0K | 362.0K | 1.1M |
| EBIT | (26.5M) | (22.4M) | (20.5M) | (28.0M) | (40.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026